RxDoctor Payments Data

Laroysha Ulmer

Psychiatric/Mental Health · Anderson, SCNPI 1598430647

Payments from drug & device makers

$2,784in general payments, 2019–2025

Across 104 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$425
  • AbbVie$420
  • Otsuka America Pharmaceutical, Inc.$409
  • Teva Pharmaceuticals USA, Inc.$362
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$314
  • Johnson & Johnson$140
  • plus $714 from 10 others

What the payments were for

  • Food & beverage$2,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,784 in reported general payments places this provider in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

See all psychiatric/mental health providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,335
Medicare patients
54
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$118,884
Abilify MaintenaAripiprazole25$65,604
Divalproex Sodium ErDivalproex Sodium32$3,918
Haloperidol Decanoate44$3,590
Aripiprazole35$1,533
Fluphenazine Decanoate15$1,374
Benztropine Mesylate74$1,062
Quetiapine Fumarate74$1,000
Olanzapine35$687
Haloperidol23$651
Buspirone Hcl41$639
Bupropion XlBupropion Hcl29$637
Risperidone35$481
Ziprasidone Hcl11$417
Clonazepam42$408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$140$118,88440 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$409$65,60425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 354 psychiatric/mental health providers in South Carolina.

Other psychiatric/mental health in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →